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Sir,
In their letter, Dr Ferretti and co-worker refer to the
perception that autoimmunity and cancer are related and may
represent ‘two sides of the same coin’. While this concept is
not new to immunologists, it has surfaced in recent years largely
due to accumulating evidence that more effective immunotherapy
of cancer is associated with autoimmune sequelae, which may
cause substantial pathology (Attia et al, 2005; Korman et al, 2005).
These recent observations coming from animal experiments and
human clinical trials once again bring to our attention the crucial
role of immune regulation in disease development and progres-
sion. While autoimmunity has always been linked to immune
dysregulation, cancer development is viewed as progressive
accumulation of genetic abnormalities in malignant cells, with
the immune system allowing or even promoting its progression
(Balkwill et al, 2005; de Visser et al, 2006). Further, the
tumours, like viruses, have evolved numerous ways of escape
from immune surveillance, as recently reviewed, so that the host
immune system is either disarmed or unable to recognise the
tumour (Whiteside, 2006).
As Dr Ferretti and co-worker point out, regulatory T cells
(Treg) represent only one mechanism of tumour escape, but
one that is clearly relevant to both autoimmunity and cancer.
Treg have been shown to regulate autoimmunity (Paust and
Cantor, 2005; Sakaguchi, 2005). More recently, Treg accumulating
at tumour sites and in the circulation of patients with cancer
(Curiel et al, 2004; Schaefer et al, 2005) are considered to be
responsible for dampening antitumour immune defences in
an antigen-specific manner (Zhou et al, 2006). The cellular
and molecular mechanisms responsible for this downregulation
of antitumour immunity by Treg are under intense scrutiny
today, but an emerging concept appears to be that the self-
nature of tumour-associated antigens may be the trigger.
Self-epitopes overexpressed by tumours could provide signals
for Treg expansion and their accumulation/activation at
tumour sites. However, Treg are a heterogeneous population
encompassing natural Treg as well as IL-10-induced and antigen-
dependent Tr1 cells and perhaps other subsets (Levings and
Roncarolo, 2005). It is yet to be determined which of these are
responsible for abetting cancer escape vs downregulating auto-
immunity. The discovery that Treg can be expanded many fold in
the presence of rapamycin (1nM) provides us with a potential
therapeutic tool in ameliorating autoimmunity (Battaglia et al,
2005; Strauss et al, 2006). In human cancer, rapamycin-driven
expansion of Treg provides the means of evaluating these cells at a
scale not possible with ex vivo isolated Treg subsets of
CD4þCD25þ T cells. These strategies are likely to clarify the
functional attributes of Treg and their contributions to disease
progression.
The question of how Treg are regulated is also important,
and the answer when available might reinforce the connection
between cancer and autoimmunity as well as uncover further
complexity of immune interactions. The role DC play in
modulating T-cell activation is well known. It now appears
that DC may also crosstalk with Treg (Chen, 2006). SOCS-1-
silenced DC have been shown to effectively break tolerance
to self and promote antitumour responses (Evel-Kabler et al,
2006). Thus, molecular signals that DC experience in the
microenvironment determine their discourse with cognate T cells.
The outcome of this discourse may well depend on the
microenvironment, including tissue- and/or tumour-derived
factors, especially cytokines and chemokines. The pleiotropic
effects of these soluble mediators are known to include Treg and
other types of immune cells (Zhang et al, 2005). The local tumour/
tissue microenvironment with its autocrine and paracrine cytokine
signalling networks is bound to orchestrate DC regulation as well
as Treg activation and, therefore, is of critical importance for
disease progression.
In patients with melanoma, the appearance of autoantibodies or
clinical manifestations of autoimmunity during therapy with
interferon a-2B is associated with good prognosis and improved
survival (Gogas et al, 2006). The mechanisms responsible for
breaking tolerance to self and simultaneously upregulating
antitumour immunity are presently unclear. A link(s) between
cancer and autoimmunity may operate at the cellular level (ie, DC
or Treg) and may involve cytokine networks or signalling
pathways such as the NF-kB pathway known to regulate
proinflammatory cytokine responses (Perkins, 2004). Nevertheless,
the predictive value of autoimmune phenomena in the upregula-
tion of antitumour immunity strongly suggests that some common
immune mechanisms are involved. Dr Ferretti and co-worker are
correct in reminding us that it will be necessary and challenging to
identify these mechanisms in order to skilfully balance the
therapeutic interface between cancer and autoimmunity. Published online 22 August 2006
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